Lisa Astor | Authors

Lisa Astor is the Associate Editorial Director for Targeted Oncology. Astor received her Bachelor of Arts in English Literature from New York University.


Building Upon Endocrine Therapy: ASCO Updates in HR+/HER2– Breast Cancer

July 14, 2022

The use of endocrine therapy as single agents serves as the control arm for many clinical studies seeking to improve upon outcomes with combination regimens and newer agents for patients with HR-positive, HER2-negative advanced breast cancer.

Frontline Bevacizumab Beneficial for Ovarian Clear Cell Carcinoma, Retrospective Analysis Shows

June 06, 2022

Bevacizumab improved progression-free survival and overall survival when added to frontline chemotherapy in patients with advanced ovarian clear cell carcinoma, according to a retrospective analysis of patients treated in Japan from 2008 to 2018.